10-K: Candel Therapeutics Reports Positive Phase 3 Data, Prolonged Survival in NSCLC and Pancreatic Cancer Trials in 10-K Filing

Candel Therapeutics' 10-K filing highlights positive clinical trial results for CAN-2409 in prostate, lung, and pancreatic cancers, along with progress in CAN-3110 for recurrent high-grade glioma.

Summary

• Candel Therapeutics' 10-K filing provides an overview of the company's clinical-stage biopharmaceutical activities, focusing on developing off-the-shelf viral immunotherapies.
• The company's lead product candidate, CAN-2409, showed statistically significant improvement in disease-free survival in a Phase 3 trial for localized prostate cancer, reducing the risk of recurrence or death by 30%.
• CAN-2409 also demonstrated prolonged overall survival in a Phase 2 trial for NSCLC patients who had an inadequate response to immune checkpoint inhibitors, with a median overall survival of 20.6 months compared to 11.6 months with standard chemotherapy.
• In pancreatic cancer, CAN-2409 showed prolonged survival in a Phase 2 trial for borderline resectable PDAC, with an estimated median overall survival of 31.4 months in the CAN-2409 group versus 12.5 months in the control group.
• CAN-3110, the company's HSV-based product candidate, is in an ongoing Phase 1b clinical trial for recurrent high-grade glioma and has received fast track and orphan drug designations from the FDA.
• The company is also developing additional novel viral immunotherapy candidates using its proprietary enLIGHTEN Discovery Platform.
• As of December 31, 2024, Candel Therapeutics had cash and cash equivalents of $102.7 million, which is expected to fund operations into the first quarter of 2027.
• The company reported a net loss of $55.2 million for the year ended December 31, 2024, and expects to continue incurring significant expenses and operating losses for the foreseeable future.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. Positive clinical trial results are balanced by the company's ongoing losses and need for additional funding. The overall tone is cautiously optimistic.

Positives

• CAN-2409 demonstrated a statistically significant improvement in disease-free survival in a Phase 3 trial for localized prostate cancer.
• CAN-2409 showed prolonged overall survival in a Phase 2 trial for NSCLC patients who had an inadequate response to immune checkpoint inhibitors.
• CAN-2409 in pancreatic cancer demonstrated prolonged survival in a Phase 2 trial for borderline resectable PDAC.
• CAN-3110 has shown promising clinical activity in recurrent high-grade glioma.
• The company has a proprietary enLIGHTEN Discovery Platform for developing additional novel viral immunotherapy candidates.
• The company has secured fast track designation for CAN-2409 and CAN-3110 in multiple indications.
• The company has secured orphan drug designation for CAN-2409 and CAN-3110 in multiple indications.

Negatives

• The company has incurred net losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future.
• The company has not generated any revenue from product sales to date and does not expect to do so in the near future.
• The company is dependent on the success of CAN-2409 and CAN-3110, and clinical trials may fail to demonstrate adequately the safety and efficacy of these product candidates.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.

Risks

• The company has a limited operating history and has not generated any revenue from product sales.
• The company will need to raise substantial additional funding, and if unable to do so, may be forced to delay, reduce, or eliminate some of its product development programs.
• The company's business is dependent on the success of CAN-2409 and CAN-3110, and clinical trials may fail to demonstrate adequately the safety and efficacy of these product candidates.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable.
• The company faces substantial competition from major pharmaceutical, specialty pharmaceutical and biotechnology companies.
• The company may be subject to product liability claims, which could be expensive and time-consuming to defend.
• The company's ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited.

Future Outlook

Candel Therapeutics expects its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027. The company plans to advance the development of CAN-2409 and CAN-3110, as well as continue to build its pipeline through its discovery platform.

Industry Context

Candel Therapeutics is operating in the competitive field of immuno-oncology, specifically focusing on viral immunotherapies. The company faces competition from major pharmaceutical and biotechnology companies, as well as academic institutions and research organizations. The success of Candel's product candidates will depend on their efficacy, safety, convenience, and price, as well as the availability of reimbursement from government and third-party payors.

Comparison to Industry Standards

• The document mentions Reckamp K et al. J Clin Onc 2022;40:2295-2306, which reports a median overall survival (mOS) of 11.6 months with SoC docetaxel-based chemotherapy in NSCLC patients with progressive disease despite ICI therapy.
• Candel's CAN-2409 showed a mOS of 20.6 months in a similar patient population, suggesting a potential improvement over the industry standard.
• The document also mentions that the prognosis for recurrent glioblastoma is dire, with mOS with second-line chemotherapy such as lomustine associated with mOS of <6-9 months.
• Candel's CAN-3110 showed a mOS of 11.8 months in the phase 1b trial in the first 41 patients as of the cutoff date of April 20, 2023, which is markedly longer than data in historical controls in the same patient population with mOS < 6-9 months.

Related Party Transactions

• The company has an exclusive license agreement with Ventagen, LLC, an entity owned in part by certain of the company's stockholders.
• The company has entered into an exclusive license agreement with Mass General Brigham (MGB).

Stakeholder Impact

• Positive clinical trial results could lead to new treatment options for patients with prostate, lung, and pancreatic cancers, as well as recurrent high-grade glioma.
• The company's financial performance and ability to secure additional funding will impact its ability to continue developing and commercializing its product candidates, affecting patients, employees, and investors.
• The company's reliance on third-party manufacturers and collaborators could impact the supply and availability of its product candidates.

Next Steps

• Initiate discussions with the FDA regarding the regulatory pathway for CAN-2409 in intermediate-to-high-risk localized prostate cancer.
• Submit a biologics license application for CAN-2409 in intermediate-to-high-risk localized prostate cancer in the fourth quarter of 2026.
• Present updated overall survival data for CAN-2409 in NSCLC in the first quarter of 2025.
• Prepare for a larger, late-stage, randomized controlled clinical trial of CAN-2409 in PDAC.
• Present initial median overall survival data for the repeat dosing cohort of CAN-3110 in the fourth quarter of 2025.

Key Dates